Sonia I. Skarlatos, PhD (September 28, 1953–August 6, 2013), was the deputy director of the Division of Cardiovascular Sciences at the National Heart, Lung, and Blood Institute (NHLBI). This article reviews her work in establishing, leading, or facilitating extramural translational research programs supported by the NHLBI, specifically focusing on her work as a consistent advocate for the advancement of gene and cell therapies.
Get full access to this article
View all access options for this article.
References
1.
BlaeseR.M., CulverK.W., MillerA.D.et al.1995. T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science, 270:475–480.
2.
BoekeA., DoumasP., ReevesL.et al.2013. Vector production in an academic environment: a tool to assess production costs. Hum. Gene Ther. Methods., 24:49–57.
3.
BuxtonD.B., SkarlatosS.I.2012. Support for cardiovascular cell therapy research at the National Heart, Lung, and Blood Institute. Circ. Res., 110:1549–1555.
4.
CollinsF.S.2010. Research agenda: opportunities for research and NIH. Science, 327:36–37.
5.
Department of Health and Human Services. 2007. National Gene Vector Biorepository and Coordinating Center (P40). NIH Solicitation. http://grants.nih.gov/grants/guide/rfa-files/RFA-RR-07-002.html. 2013September.
6.
GalisZ.S., BlackJ.B., SkarlatosS.I.2013. National Heart, Lung, and Blood Institute and the translation of cardiovascular discoveries into therapeutic approaches. Circ. Res., 112:1212–1218.
7.
LauerM.S., SkarlatosS.I.2010. Translational research for cardiovascular diseases at the National Heart, Lung, and Blood Institute: moving from bench to bedside and from bedside to community. Circulation, 121:929–933.
8.
McDonaldC.L., BensonJ., CornettaK.et al.2013. Advancing translational research through the NHLBI Gene Therapy Resource Program (GTRP)Hum. Gene Ther. Clin. Dev., 24:5–10.
9.
MoyéL.A., SayreS.L., WestbrookL.et al.2011. Oversight and management of a cell therapy clinical trial network: experience and lessons learned. Contemp. Clin. Trials, 32:614–619.
10.
PerinE.C., WillersonJ.T., PepineC.J.et al.2012. Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial. JAMA, 307:1717–1726.
11.
RichmanS., GeeA.P., McKennaD.H.et al.2012. Factors affecting the turnaround time for manufacturing, testing, and release of cellular therapy products prepared at multiple sites in support of multicenter cardiovascular regenerative medicine protocols: a Cardiothoracic Cell Therapy Research Network (CCTRN) study. Transfusion, 52:2225–2233.
12.
SimariR.D., MoyéL.A., SkarlatosS.I.et al.2010. Development of a network to test strategies in cardiovascular cell delivery: the NHLBI-sponsored Cardiovascular Cell Therapy Research Network (CTTRN)J. Cardiovasc. Trans. Res., 3:30–36.
13.
SkarlatosS.I.2007. New programs for gene- and cell-based therapies at NHLBI. Clin. Pharmacol. Ther., 82:334–336.
14.
TarantalA.F., SkarlatosS.I.2012. Center for Fetal Monkey Gene Transfer for Heart, Lung, and Blood Diseases: an NHLBI resource for the gene therapy community. Hum. Gene. Ther., 23:1130–1135.
15.
TraverseJ.H., HenryT.D., EllisS.G.et al.2011. Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the late TIME randomized trial. JAMA, 306:2110–2119.
16.
TraverseJ.H., HenryT.D., PepineC.J.et al.2012. Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial. JAMA, 308:2380–2389.
17.
WooS.L., SkarlatosS.I., JoyceM.M.et al.Heart LungBlood Diseases Working Group. 2006. Critical resources for gene therapy in Heart, Lung, and Blood Diseases Working Group. Mol Ther., 13:641–643.
